8-K
filed February 26, 2026, 6:59 PM ET
ticker VIR
CIK 0001706431
other material
confidence high
sentiment neutral
materiality 0.70
Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share
Vir Biotechnology, Inc.
- Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
- Net proceeds estimated at $141.1M, or $162.3M if over-allotment fully exercised.
- Underwriters include Goldman Sachs, Leerink Partners, Evercore, Barclays; closing expected Feb 27, 2026.
- Proceeds for general corporate purposes; shares sold under existing S-3ASR shelf registration.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-077416
- form_type
- 8-K
- ticker
- VIR
- cik
- 0001706431
- company_name
- Vir Biotechnology, Inc.
- filed_at
- 2026-02-26T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:35.951672+00:00
- generated_at
- 2026-05-15T23:41:10.086027+00:00
- sec_items
- ["1.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-077416
- json_url
- https://secwatch.observer/filing/0001193125-26-077416.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-077416.md
- text_url
- https://secwatch.observer/filing/0001193125-26-077416.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/0001193125-26-077416-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1706431/000119312526077416/d85338d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).
Filing page
SEC filing
GIPR
Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit
GENERATION INCOME PROPERTIES, INC.
June 1, 2026, 5:27 PM ET
other_material
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent
Filing page
SEC filing
LOKV
Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54
Live Oak Acquisition Corp. V
June 1, 2026, 5:00 PM ET
other_material
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (" Live Oak "), and HB Strategies LLC (" Seller " or " FPA Investor ") entered into an agreement (the " Forward Purchase Agreement ") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the " Forward Purchase Transaction ") in connection with Live Oak’s proposed initial business combination (the " Business Combination ") with Teamshares Inc., a Delaware corporation (" Teamshares " and the surviving public company following consummation of the Business Combination, the " Combined Company "), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the " Merger Agreement ").
Filing page
SEC filing
AIB
Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline
BlockchAIn Digital Infrastructure, Inc.
June 1, 2026, 4:57 PM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).
Filing page
SEC filing
BBDC
Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments
Barings BDC, Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).
Filing page
SEC filing
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
CITR
CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights
CitroTech Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock
Filing page
SEC filing
LTRX
Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M
LANTRONIX INC
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering).
Comparable filing
On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.